Company No:
Contents
Note | 31.12.2023 | 31.12.2022 | ||
£ | £ | |||
Fixed assets | ||||
Investments | 3 |
|
|
|
2 | 2 | |||
Current assets | ||||
Debtors | 4 |
|
|
|
Cash at bank and in hand |
|
|
||
25,923 | 19,160 | |||
Creditors: amounts falling due within one year | 5 | (
|
(
|
|
Net current assets | 9,947 | 7,339 | ||
Total assets less current liabilities | 9,949 | 7,341 | ||
Net assets |
|
|
||
Capital and reserves | ||||
Called-up share capital |
|
|
||
Profit and loss account |
|
|
||
Total shareholder's funds |
|
|
Directors' responsibilities:
The financial statements of Injury Assess Medicals Limited (registered number:
A Keeling
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.
Injury Assess Medicals Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 5 Woodcote View, Wilmslow, SK9 2DT, England, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
Turnover is derived from intermediation between medical professionals and legal teams on behalf of solicitors.
Revenue is measured at the fair value of invoices raised in respect of physiotherapy and medical appointments, net of discounts and excluding value added tax, and is recognised at the date the appointment is booked.
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.
Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.
Investments
Investments in subsidiaries are measured at cost less accumulated impairment.
Year ended 31.12.2023 |
Period from 01.12.2021 to 31.12.2022 |
||
Number | Number | ||
Monthly average number of persons employed by the Company during the period |
|
|
The directors did not receive any remuneration in the year (2022: £nil).
Investments in subsidiaries
31.12.2023 | |
£ | |
Cost | |
At 01 January 2023 |
|
At 31 December 2023 |
|
Carrying value at 31 December 2023 |
|
Carrying value at 31 December 2022 |
|
31.12.2023 | 31.12.2022 | ||
£ | £ | ||
Trade debtors |
|
|
|
Amounts owed by directors |
|
|
|
Other debtors |
|
|
|
|
|
31.12.2023 | 31.12.2022 | ||
£ | £ | ||
Trade creditors |
|
|
|
Amounts owed to Group undertakings |
|
|
|
Corporation tax |
|
|
|
Other taxation and social security |
|
|
|
Other creditors |
|
|
|
|
|
Transactions with the entity's directors
During the year advances of £3,700 were paid to Mrs A Keeling. The maximum advanced during the year was £13,250 (2022: £9,550). No repayments were made during the year (2022: £nil). At the balance sheet date the outstanding balance was £13,524 (2022: £9,550). The loan attracts interest at 2.25% and is repayable on demand.
Other related party transactions
During the prior year, the company paid expenses on behalf of a company with directors in common. The amount advanced was £nil (2022: £848). At the balance sheet date, the outstanding balance was £848 (2022: £848).